Trochleoplasty in the Management of Objective Patellar Instability: a Personalized Surgical Approach for the Prevention of Recurrence in Patients With Trochlear Dysplasia (TROCHLEO-CARE)

November 10, 2026 updated by: Stefano Zaffagnini

This is a multicentre, international, non-profit observational study aimed at prospectively validating a personalized diagnostic and therapeutic algorithm based on the Dejour v3.0 classification in patients with recurrent objective patellar instability and trochlear dysplasia.

The primary objective is to compare treatment failure rates at 24 months between patients with severe trochlear dysplasia (trochlear bump >5 mm) treated with trochleoplasty and MPFL reconstruction, and a retrospective control group with similar trochlear morphology treated without trochleoplasty.

Secondary outcomes include clinical and functional outcomes assessed using validated scores (IKDC, Kujala, Tegner and BPII 2.0), cartilage status assessed by MRI using the MOAKS score, and postoperative complications, particularly arthrofibrosis.

Patients aged 14-49 years will be enrolled at IRCCS Istituto Ortopedico Rizzoli and Lyon Ortho Clinic. The study includes both a prospective cohort managed according to the Dejour v3.0 algorithm and a retrospective historical control cohort. Follow-up assessments will be performed up to 24 months after surgery.

The study is planned to start on October 1, 2026, with an expected completion date of September 30, 2029. A total sample size of 152 patients (76 per group) is planned.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

152

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Bologna
      • Bologna, Bologna, Italy, 40136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study will be conducted within the facilities of the Orthopedic and Traumatology Clinic II Unit at the IRCCS Istituto Ortopedico Rizzoli and at the Lyon Ortho Clinic. Surgical procedures will be performed at both these institutions.

Patients will be asked to sign an informed consent during the hospital stay and after signing the informed consent will be asked to complete a questionnaire on the preoperative condition.

Clinical follow-up visits will be carried out at the outpatient clinics of the IRCCS Istituto Ortopedico Rizzoli as well as at the Lyon Ortho Clinic.

Description

Inclusion Criteria study group:

  • Patients aged ≥14 years and <50 years
  • Male and female patients
  • Patients with a clinical history of recurrent objective patellar instability (OPI)
  • Provision of written informed consent to participate in the study
  • Patients who performed preoperative imaging studies (MRI) that confirmed the diagnosis and the need for treatment based on the above mentioned criteria (type 3 dysplasia with a bump >5mm)

Exclusion Criteria study group:

  • Patients with established knee osteoarthritis (K-L ≥2)
  • Patients with concomitant ligament injuries (including anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), or collateral ligaments)
  • Patients with a history of prior knee surgery for conditions other than patellar instability
  • Patients who have previously undergone surgical procedures for patellar instability (OPI)
  • Patients with incomplete or inadequate MRI data

Inclusion Criteria control group:

  • Patients aged ≥14 years and <50 years treated for OPI with another procedure except trochleoplasty in the two reference centres from 2022 to 2024
  • Male and female patients
  • Provision of written informed consent to participate in the study
  • Patients who performed preoperative imaging studies (MRI/CT scan) that confirmed a type 3 dysplasia with a bump >5mm

Exclusion Criteria control group:

  • Patients with concomitant ligament injuries (including anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), or collateral ligaments)
  • Patients with a history of prior knee surgery for conditions other than patellar instability
  • Patients who have had previously undergone surgical procedures for patellar instability (OPI) at the time of the MRI/CT scan
  • Patients with incomplete or inadequate MRI or CT scan data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Case group

Patients who performed preoperative imaging studies (MRI) that confirmed the diagnosis and the need for treatment based on the above mentioned criteria (type 3 dysplasia with a bump >5mm). They are treated according to the Dejour v3.0 algorithm, which involves trochleoplasty combined with medial patellofemoral ligament (MPFL) reconstruction.

Control group

The control group includes patients with comparable anatomical characteristics who were previously treated without trochleoplasty.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Failure rates
Time Frame: At 24 months

Defined as reoperation for subsequent atraumatic patellar luxation or persistent instability at 24 months. They will be registered in the CRF during the follow-up visits or during the telephonic contact in case of missing follow-ups. This could also be assessed through the clinical documentation of the patient, in case of missing data.

At 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2027

Primary Completion (Estimated)

September 1, 2029

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • TROCHLEO-CARE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.